AgomAb Therapeutics (NASDAQ:AGMB) Sets New 12-Month High – What’s Next?

AgomAb Therapeutics NV (NASDAQ:AGMB)’s share price reached a new 52-week high on Tuesday . The company traded as high as $17.82 and last traded at $17.82, with a volume of 198739 shares. The stock had previously closed at $13.81.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on AGMB. Morgan Stanley initiated coverage on shares of AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “overweight” rating and a $28.00 price target for the company. JPMorgan Chase & Co. started coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They issued an “overweight” rating and a $32.00 price objective on the stock. Leerink Partners started coverage on AgomAb Therapeutics in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $36.00 target price for the company. Zacks Research upgraded AgomAb Therapeutics to a “hold” rating in a research note on Wednesday, March 4th. Finally, HC Wainwright initiated coverage on AgomAb Therapeutics in a report on Monday, June 22nd. They issued a “buy” rating and a $35.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $32.75.

AgomAb Therapeutics Price Performance

The business has a 50 day moving average price of $11.32.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.